Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: So. Much. News.

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.


Related Content

Spark's Luxturna Approval Ushers In A New Gene Therapy Era
Keeping Track: Approvals, A Burst Of Submissions, And Some Priority Reviews
Keeping Track: Another Gene Therapy Approval, Several Priority Review Designations, And Many Resubmissions
Keeping Track: A Lilly Breast Cancer Approval, A Couple Of CRLs, And A Plethora Of Priority Reviews
Agile's Phase III Data For Twirla Patch Fall Flat, Raise Doubts On Approval
Keeping Track: Neurology And Pain Products Keep FDA Occupied
Basilea's Ceftobiprole Dubbed Qualified Infectious Disease Product
Basilea Ceftobiprole Saga Wages On; U.S. Development Ditched
Santen eyes uveitis market with top-line sirolimus data
Agile SEC filing reveals FDA rejection for Twirla contraceptive


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts